NCT04024761View on ClinicalTrials.gov

A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 31, 2019

Primary Completion Date

December 1, 2025

Study Completion Date

December 1, 2025

Conditions
Acute Myeloid LeukemiaMyelodysplastic SyndromesMyeloproliferative NeoplasmJuvenile Myelomonocytic Leukemia
Interventions
BIOLOGICAL

CIML NK

CIML NK cells have enhanced ability to recognize and kill leukemia targets

DRUG

Fludarabine

Fludarabine is a chemotherapy agent

DRUG

Cyclophosphamide

Cyclophosphamide (CP), also known as cytophosphane among other names, is a chemotherapy agent

Trial Locations (2)

02115

Boston Children's Hospital, Boston

Dana Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

The Leukemia and Lymphoma Society

OTHER

lead

Dana-Farber Cancer Institute

OTHER